Paris, October 21st, 2023 - Truffle Capital is pleased with Abivax's highly successful Nasdaq IPO, despite a challenging stock market environment. Abivax is a clinical-stage biotechnology company focused on the development of drugs that exploit the body's natural regulatory mechanisms to modulate the immune response of patients suffering from chronic inflammatory diseases.
For further information, refer to the Abivax press release announcing the pricing of its IPO on the Nasdaq Global Market, and the Abivax website.
Abivax, founded in 2013 by Truffle Capital, had raised 58 million euros during its IPO on Euronext, in 2015. To date, this remains the largest IPO of a biotech company on Euronext Paris. The IPO announced yesterday is expected to rank as the largest IPO ever carried out by a French biotech company on the Nasdaq. Following this IPO, Abivax is expected to become the third company in the world to have secured the most financing in the biotech sector in 2023.
